Abstract
Due to complexity of advanced epithelial cancers, it is necessary to implement patient specific combination therapies if we are to markedly improve patient outcomes. However, our ability to select and implement patient specific combination therapies based on dynamic molecular changes in the tumor and tumor ecosystem in response to therapy remains extremely limited. In a pilot study, we evaluated the feasibility of real-time deep analysis of serial tumor samples from triple negative breast cancer patients to identify mechanisms of resistance and treatment opportunities as they emerge under therapeutic stress engendered by poly-ADP-ribose polymerase (PARP) inhibitors (PARPi). Although PARP inhibition was consistently observed in all patients, deep molecular analysis of the tumor and its ecosystem revealed insights into potentially effective therapeutic PARPi combinations. In a BRCA-mutant basal breast cancer exceptional long-term survivor, we noted striking PARPi-induced tumor destruction accompanied by a marked infiltration of immune cells containing CD8 effector cells, consistent with pre-clinical evidence for association between STING mediated immune activation and benefit from PARPi and immunotherapy. Tumor cells in the exceptional responder underwent extensive protein network rewiring in response to PARP inhibition. In contrast, there were minimal changes in the ecosystem of a luminal androgen receptor (LAR) rapid progressor in response to PARPi likely due to indifference to the effects of PARP inhibition. In this rapid progressor, there was minimal evidence of immune activation or protein network rewiring in response to PARPi, despite PARP being inhibited, and no clinical benefit was noted for this participant. Together, deep real-time analysis of longitudinal biopsies identified a suite of PARPi-induced emergent changes including immune activation, DNA damage checkpoint activation, apoptosis and signaling pathways including RTK, PI3K-AKT and RAS-MAPK, that could be used to select patient specific combination therapies, based on tumor and immune state changes that are likely to benefit specific patients.
Highlights
Longitudinal analysis of serial tumor samples in real-time identifies adaptive mechanisms of resistance to PARPi therapies.
Deep molecular analysis of the tumor reveals insights into potentially effective therapeutic PARPi combinations.
Extensive protein network rewiring, microenvironment and immune state changes are assessable factors for patient specific combination therapies.
Competing Interest Statement
GBM: Consultant/Scientific Advisory Board (AstraZeneca, Chrysalis, ImmunoMET, Ionis, Lilly USA, LLC, PDX Pharma, Signalchem Lifesciences, Symphogen, Tarveda); Stock/Options/Financial Companies (Catena Pharmaceuticals, ImmunoMet, SignalChem, Spindletop Ventures, Tarveda); Licensed Technology Companies (HRD assay to Myriad Genetics, DSP to Nanostring); CLC: Consultant/Scientific Advisory Board (Amgen, Cepheid/Daneher); Stock/Options (Guardant Health); RB: inventor on patents related to KBU2046 and therapeutically targeting cancer motility, and co-owner of Third Coast Therapeutics, which has an option to license those patents; JV: Consultant/Scientific Advisory Board (Seattle Genetics/Astellas), research funding (Celldex, Innocrin Pharma, Roche/Genentech, Novartis, Merck, Fortis Therapeutics). LMC: paid consultant for Cell Signaling Technologies, received reagent and/or research support from Plexxikon Inc., Pharmacyclics, Inc., Acerta Pharma, LLC, Deciphera Pharmaceuticals, LLC, Genentech, Inc., Roche Glycart AG, Syndax Pharmaceuticals Inc., and NanoString Technologies, and is a member of the Scientific Advisory Boards of Syndax Pharmaceuticals, Carisma Therapeutics, Zymeworks, Inc, Verseau Therapeutics, Kineta, Inc., and Cytomix Therapeutics, Inc. ARG: Siemens Speaker's Bureau, Consultant for Takeda Pharmaceuticals, Inc., Expert Witness for Rice, Dolan & Kershaw and Witherspoon & Kelley. PTS: IP licensed to Cepheid, equity in convergent genomics, consulting for Foundation Medicine. JGW: Business Relationships (Abbott Diagnostics, Danaher (formerly Cepheid), PDX Pharmaceuticals and Thermo Fisher Scientific (formerly FEI), Zeiss, Micron), Company Ownership Positions (Convergent Genomics, KromaTid, PDX Pharmaceuticals), Full- or Part-time Employment or Service as an Officer, Board Member or Other Position of Leadership (Oregon Health & Science University; Cooperative Japan-United States Radiation Effects Research Foundation), Consulting or Advisory Relationships (APOBEC Cancer Program, University of Minnesota; Comprehensive Cancer Center, University of New Mexico (UNM); MJ Murdock Charitable Trust; New Leaf Ventures; Susan G. Komen for the Cure, University of Denver Medical Center), Stock Ownership (Abbott Diagnostics, AbbVie, Alphabet, Amgen, Amazon, Apple Corporation, Berkshire Hathaway, Cameco, Chevron, ConocoPhillips, Cisco Systems, Clorox, Colgate-Palmolive, Crown Castle, Devon Energy, Disney, Exxon Mobile, General Electric, Gilead, Intel, Nasdaq, Nvidia, PepsiCo, Philips, Procter & Gamble, Swiss Helveita, Walt Disney, Wells Fargo, and Zimmer Biomet).
Clinical Trial
The clinical trial was registered as NCT03544125 under ClinicalTrials.gov. The trial was registered prospectively to this study.
Funding Statement
This project was supported by the OHSU Knight Cancer Institute NCI Cancer Center Support Grant P30CA069533. GBM: NCI grant U01CA217842, Komen SAC110052 and Breast Cancer Research Foundation BCRF□19-110. ML: Ovarian Cancer Research Alliance and Ruth and Steve Anderson, in honor of Shae Anderson Gerlinger. YHC: NCI grant U54CA209988 and U2CCA233280. RB: DOD PC190174 and PC141395, Veterans Administration Merit Award IBX002842A, NIH R01GM086688 and P30 CA69533, Prospect Creek Foundation. JWG: NIH/NCI U2C CA233280; NIH/NCI U54 CA209988; NIH U54 HG008100; NIH/NCI P30 CA69533; Brenden Colson; PDX Pharmaceuticals, LLC/NCI SRA-14-040 (R44, N43-CO-2013-00078); NIH U01 CA195469, Harvard University Subaward; Susan G. Komen Foundation SAC110012. ARG: R01 DK117459-01, 1 U2C-CA23380-01, The V Foundation for Cancer Research T2015-004. JG: U24-CA231877, U2C-CA233280. AC: U2C-CA233280. PTS: NIH U24CA210957, U01CA195469, P30CA069533, U01CA199315, U01CA232819, R01CA248383, R01, U01, DOD BC151431P1, Knight Cancer Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was reviewed and approved by the OHSU Institutional Review Board.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
There is no external datasets or online supplementary material.
